Waning antibody responses in COVID-19: what can we learn from the analysis of other coronaviruses?
Open Access
- 29 July 2021
- journal article
- review article
- Published by Springer Science and Business Media LLC in Infection
- Vol. 50 (1), 11-25
- https://doi.org/10.1007/s15010-021-01664-z
Abstract
Objectives The coronavirus disease 2019 (COVID-19), caused by the novel betacoronavirus severe acute respiratory syndrome 2 (SARS-CoV-2), was declared a pandemic in March 2020. Due to the continuing surge in incidence and mortality globally, determining whether protective, long-term immunity develops after initial infection or vaccination has become critical. Methods/Results In this narrative review, we evaluate the latest understanding of antibody-mediated immunity to SARS-CoV-2 and to other coronaviruses (SARS-CoV, Middle East respiratory syndrome coronavirus and the four endemic human coronaviruses) in order to predict the consequences of antibody waning on long-term immunity against SARS-CoV-2. We summarise their antibody dynamics, including the potential effects of cross-reactivity and antibody waning on vaccination and other public health strategies. At present, based on our comparison with other coronaviruses we estimate that natural antibody-mediated protection for SARS-CoV-2 is likely to last for 1–2 years and therefore, if vaccine-induced antibodies follow a similar course, booster doses may be required. However, other factors such as memory B- and T-cells and new viral strains will also affect the duration of both natural and vaccine-mediated immunity. Conclusion Overall, antibody titres required for protection are yet to be established and inaccuracies of serological methods may be affecting this. We expect that with standardisation of serological testing and studies with longer follow-up, the implications of antibody waning will become clearer.Keywords
This publication has 162 references indexed in Scilit:
- First infection by all four non-severe acute respiratory syndrome human coronaviruses takes place during childhoodBMC Infectious Diseases, 2013
- A Novel Chimpanzee Adenovirus Vector with Low Human Seroprevalence: Improved Systems for Vector Derivation and Comparative ImmunogenicityPLOS ONE, 2012
- Clinical Assessment of a Recombinant Simian Adenovirus ChAd63: A Potent New Vaccine VectorThe Journal of Infectious Diseases, 2012
- Epidemiology and Clinical Presentations of the Four Human Coronaviruses 229E, HKU1, NL63, and OC43 Detected over 3 Years Using a Novel Multiplex Real-Time PCR MethodJournal of Clinical Microbiology, 2010
- Understanding Human Coronavirus HCoV-NL63~!2009-11-13~!2010-04-09~!2010-05-25~!The Open Virology Journal, 2010
- Human Coronavirus NL63 and 229E Seroconversion in ChildrenJournal of Clinical Microbiology, 2008
- Duration of Antibody Responses after Severe Acute Respiratory SyndromeEmerging Infectious Diseases, 2007
- Use of convalescent plasma therapy in SARS patients in Hong KongEuropean Journal of Clinical Microbiology & Infectious Diseases, 2004
- Longitudinal Profile of Immunoglobulin G (IgG), IgM, and IgA Antibodies against the Severe Acute Respiratory Syndrome (SARS) Coronavirus Nucleocapsid Protein in Patients with Pneumonia Due to the SARS CoronavirusClinical and Vaccine Immunology, 2004
- The time course of the immune response to experimental coronavirus infection of manEpidemiology and Infection, 1990